Altavita D3
Vitamin D3 medicine available in Malta
Altavita is indicated for the prevention and treatment of Vitamin D Deficiency*.
Prevention of Vitamin D Deficiency
Altavita 25,000 iu soft capsules are licensed for the prevention of Vitamin D Deficiency. The recommended dose is 1 x Altavita 25,000 iu soft capsule monthly.
Treatment of Vitamin D Deficiency
Altavita 25,000 iu soft capsules are licensed for the treatment of Vitamin D Deficiency. The recommended dose is 2 x Altavita 25,000 iu soft capsules per week for 6 – 8 weeks
Altavita is also licensed as an adjunct to specific therapy for osteoporosis in patients with Vitamin D deficiency or at risk of Vitamin D insufficiency
Altavita is a licensed prescription only medicine
Vitamin D supplements that can be bought in a pharmacy are manufactured to different standards than prescription-only medicines. You can be sure with a prescription-only medicine such as Altavita D3 25,000 IU soft capsules, that the medicine will provide a consistent amount of vitamin D at the quantity specified on the pack.1,2
Always prescribe Altavita® D3 by brand name and presentation
*This is the recommended dosage for prevention and treatment of vitamin D deficiency in adults. Please see SPC for paediatric doses.
Altavita Dose Card
Webinars
Guidelines
Royal Osteoporosis Society guidelines
FRAX Tool
References
- Altavita D3 25,000 IU soft capsules Summary of Characteristics available on medicines.ie
- Sanjay Garg et al 2012, Evaluation of vitamin D medicines and dietary supplements and the physicochemical analysis of selected formulations; The journal of nutrition, health & aging volume 17, pages 158–161 https://link.springer.com/article/10.1007/s12603-012-0090-4
Consilient Health Ltd
Block 2A Richview Office Park
Clonskeagh, Dublin 14
T. +353 (0)1 2057760
info@consilienthealth.com
Healthcare professionals are asked to report any suspected adverse
reactions via: www.medicinesauthority.gov.mt/adrportal or via email: postlicensing.medicinesauthority@gov.mt or by contacting Vivian Corporation Ltd at pv@viviancorp.com or +356 22588600.
Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 01 2057766
The information on this page is intended for Health Care Professional who practice in Ireland and Malta only
IE-ALT-386(7), Date of preparation: September 2025
Vivian Corporation Ltd
The Hub,
Troubridge Street,
Marsa, MRS1113, Malta
T. +356 2258 8600
viviancorp.com